Treatment effects of antithrombin in septic patients with disseminated intravascular coagulation (DIC).

Treatment effects of antithrombin in septic patients with disseminated intravascular coagulation (DIC). - Antithrombin and sepsis-associated DIC.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000882

Enrollment

200

Registered

2007-12-01

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis associated with disseminated intravascular coagulation (DIC).

Interventions

Antithrombin III, Three days, 30 IU/kg, One administration/day No treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) ACCP/SCCM-defined sepsis criteria, 2) Japanese Association for Acute Medicine-defined DIC criteria score > 4, 3) Antithrombin level >50% and <80%. The patient fulfilles 1), 2), and 3).

Exclusion criteria

Exclusion criteria: 1) < Fifteen years of age, 2) Hematopoetic malignancy, 3) Comcomitant treatment with cartinostatics or irradiation, 4) Liver cirrhosis classified as Child-Pugh C, 5) Early phase of trauma and burn injury.

Design outcomes

Primary

Measure	Time frame
Improvement of DIC score, coagulation and fibrinolytic markers on the four days after antithrombin treatment.	—

Secondary

Measure	Time frame
Twenty-eight day mortality	—

Countries

Japan

Contacts

Public ContactSatoshi Gando

Hokkaido University Graduate School of Medicine Acute and Critical Care Medicine

gando@med.hokudai.ac.jp011-706-7377

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026